The aim of this study is to investigate cancer patients’ response and side effects associated with transdermal therapeutic fentanyl (TTS-F), whose pain was hardly controlled by nonweak/weak opioids in Taiwan. From 2005 to 2006, 822 outpatients received TTS-F to collect pain assessment forms and diaries for 4 weeks. Most (78.7%) patients were initially prescribed 25 μg/h TTS-F. Doses were adjusted weekly at clinicians’ discretion, according to pain assessment and side effects. Patients receiving 50 μg/h, 75 μg/h, and > 75 μg/h TTS-F had increased from 17.5% to 32.1%, 1.8% to 3.4%, and 1.9% to 2.2%, respectively, by week 2; further small increases were found in weeks 3 and 4. Pain palliation improved from 60.6% during week 1 to 78.6% at week 4. The common adverse effects were nausea/vomiting. Patient’s compliance was >90%. This study found that the TTS-F is effective and well tolerated.
World Health Organization.Cancer pain relief and palliative care. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser. 1990;804:1-75.
2.
WHO.Cancer Pain Relief . With a Guide to Opioid Availability. Singapore: World Health Organization; 1996.
3.
Grond S., Radbruch L., Lehmann KAClinical pharmacokinetics of transdermal opioids: focus on transdermal fentanyl . Clin Pharmacokinet. 2000;38(1):59-89.
4.
Southam MATransdermal fentanyl therapy: system design, pharmacokinetics and efficacy . Anticancer Drugs. 1995;6(suppl 3):29-34.
5.
Payne R.Factors influencing quality of life in cancer patients: the role of transdermal fentanyl in the management of pain. Semin Oncol . 1998;25(3 suppl 7):47-53.
6.
Sloan PA, Moulin DE, Hays H.A clinical evaluation of transdermal therapeutic system fentanyl for the treatment of cancer pain. J Pain Symptom Manage. 1998 ; 16(2):102-111.
7.
Grond S., Zech D., Lehmann KA, Radbruch L., Breitenbach H., Hertel D.Transdermal fentanyl in the long-term treatment of cancer pain: a prospective study of 50 patients with advanced cancer of the gastrointestinal tract or the head and neck region. Pain. 1997 ; 69(1-2):191-198.
8.
Jeal W., Benfield P.Transdermal fentanyl. A review of its pharmacological properties and therapeutic efficacy in pain control. Drugs. 1997;53(1):109-138.
9.
Mystakidou K. , Befon S., Kouskouni E., et al. From codeine to transdermal fentanyl for cancer pain control: a safety and efficacy clinical trial. Anticancer Res. 2001; 21(3C):2225-2230.
10.
Hammack JE, Mailliard JA, Loprinzi CL, et al. Transdermal fentanyl in the management of cancer pain in ambulatory patients: an open-label pilot study. J Pain Symptom Manage . 1996;12(4):234-240.
11.
Korte W., de Stoutz N., Morant R.Day-to-day titration to initiate transdermal fentanyl in patients with cancer pain: short- and long-term experiences in a prospective study of 39 patients . J Pain Symptom Manage. 1996 ; 11(3):139-146.
12.
Vielvoye-Kerkmeer AP, Mattern C., Uitendaal MPTransdermal fentanyl in opioid-naive cancer pain patients: an open trial using transdermal fentanyl for the treatment of chronic cancer pain in opioid-naive patients and a group using codeine . J Pain Symptom Manage. 2000 ;19(3):185-192.
13.
Radbruch L. , Sabatowski R., Petzke F., Brunsch-Radbruch A., Grond S., Lehmann KATransdermal fentanyl for the management of cancer pain: a survey of 1005 patients . Palliat Med. 2001;15(4):309-321.
14.
Mystakidou K., Befon S., Tsilika E., Dardoufas K., Georgaki S., Vlahos L.Use of TTS fentanyl as a single opioid for cancer pain relief: a safety and efficacy clinical trial in patients naïve to mild or strong opioids. Oncology . 2002;62(1):9-16.
15.
Mystakidou K., Parpa E., Tsilika E., et al. Pain management of cancer patients with transdermal fentanyl: a study of 1828 step I, II, & III transfers . J Pain. 2004; 5(2):119-132.
16.
Tawfik MO, Bryuzgin V., Kourteva G.FEN-INT-20 Study Group.Use of transdermal fentanyl without prior opioid stabilization in patients with cancer pain. Curr Med Res Opin. 2004;20(3):259-267.
17.
van Seventer R., Smit JM, Schipper RM, Wicks MA, Zuurmond WWComparison of TTS-fentanyl with sustained-release oral morphine in the treatment of patients not using opioids for mild-to-moderate pain. Curr Med Res Opin. 2003;19(6):457-469.
18.
Jarlbaek L. , Hallas J., Kragstrup J., Andersen M.Cancer patients’ first treatment episode with opioids: a pharmaco-epidemiological perspective . Support Care Cancer. 2006;14(4):340-347.
19.
Radbruch L. , Sabatowski R., Loick G., et al. Constipation and the use of laxatives: a comparison between transdermal fentanyl and oral morphine. Palliat Med. 2000; 14(2):111-119.
20.
Ahmedzai S. , Brooks D.Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. The TTS-Fentanyl Comparative Trial Group. J Pain Symptom Manage . 1997;13(5):254-261.
21.
Donner B., Zenz M., Tryba M., Strumpf M.Direct conversion from oral morphine to transdermal fentanyl: a multicenter study in patients with cancer pain. Pain. 1996;64(3):527-534.
22.
Dworkin RH, Turk DC, Wyrwich KW, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain . 2008;9(2):105-121.
